A new strategy for helping a larger portion of patients

Molecularly guided therapies have changed the outcome for a growing proportion of cancer patients, but this approach is still largely untapped for the majority of individuals with acute myeloid leukemias and myelodysplastic syndromes. NMI-900 therapy coupled with a novel RNA biomarker provides a new strategy for helping a larger portion of patients with a variety of malignant blood disorders.